CoChat

Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Kwak, Jae-Yong, Kim, Sung-Hyun, Oh, Suk Joong, Zang, Dae Young, Kim, Hawk, Kim, Jeong-A, Do, Young Rok, Kim, Hyeoung Joon, Park, Joon Seong, Choi, Chul Won, Lee, Won Sik, Mun, Yeung-Chul, Kong, Jee Hyun, Chung, Joo Seop, Shin, Ho-Jin, Kim, Dae-Young, Park, Jinny, Jung, Chul Won, Bunworasate, Udomsak, Comia, Narcisa Sonia, Jootar, Saengsuree, Reksodiputro, Arry Harryanto, Caguioa, Priscilla B., Lee, Sung-Eun, Kim, Dong-Wook · 2017 · Clinical Cancer Research
Cited by 78

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly diagnosed or with insufficient response to other TKIs. This study was conducted to evaluate the efficacy and safety of radotinib as first-line therapy for CML-CP. Experimental Design: This multinational, open-label study assigned patients (1:1:1) to one of two twice-daily radotinib doses, or imatinib daily. The primary endpoint was major molecular response (MMR) by 12 months. Results: Two hundred forty-one patients were randomized to receive radotinib 300 mg (n = 79) or 400 mg twice-daily (n = 81), or imatinib 400 mg daily (n = 81). MMR rates by 12 months were higher in patients receiving radotinib 300 mg (52%) or radotinib 400 mg twice-daily (46%) versus imatinib (30%; P = 0.0044 and P = 0.0342, respectively). Complete cytogenetic response (CCyR) rates by 12 months were higher for radotinib 300 mg (91%) versus imatinib (77%; P = 0.0120). Early molecular response at 3 months occurred in 86% and 87% of patients receiving radotinib 300 mg and radotinib 400 mg, respectively, and 71% of those receiving imatinib. By 12 months, no patients had progression to accelerated phase or blast crisis. Most adverse events were manageable with dose reduction. Conclusions: Radotinib demonstrated superiority over imatinib in CCyR and MMR in patients newly diagnosed with Philadelphia chromosome–positive CML-CP. This trial was registered at www.clinicaltrials.gov as NCT01511289. Clin Cancer Res; 23(23); 7180–8. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-0957

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 78

Metadata

Authors
Kwak, J.-Y., Kim, S.-H., Oh, S. J., Zang, D. Y., Kim, H., Kim, J.-A., Do, Y. R., Kim, H. J., Park, J. S., Choi, C. W., Lee, W. S., Mun, Y.-C., Kong, J. H., Chung, J. S., Shin, H.-J., Kim, D.-Y., Park, J., Jung, C. W., Bunworasate, U., Comia, N. S., Jootar, S., Reksodiputro, A. H., Caguioa, P. B., Lee, S.-E., & Kim, D.-W.
Venue
Clinical Cancer Research
Published
2017-11-30
Volume
23
Issue
23
Pages
7180-7188
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2759146932
Cited by
78
References
2
FWCI
5.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0957
The paper
Kwak, J.-Y., Kim, S.-H., Oh, S. J., Zang, D. Y., Kim, H., Kim, J.-A., Do, Y. R., Kim, H. J., Park, J. S., Choi, C. W., Lee, W. S., Mun, Y.-C., Kong, J. H., Chung, J. S., Shin, H.-J., Kim, D.-Y., Park, J., Jung, C. W., Bunworasate, U., . . . Kim, D.-W. (2017). Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0957

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.